Cadila bags USFDA approval for arthritis tablets

Zydus Cadila informed the bourses that it has received the final USFDA approval to market Leflunomide Tablets USP, 10 mg and 20 mg.

The said medicine is used to treat rheumatoid arthritis. This medicine helps reduce joint damage and disability and pain and swelling related to arthritis.

The group has 263 approvals and has so far filed over 350 ANDAs since the commencement of the filing process.

Cadila's FY18 revenue mix comprised US Formulations (50 per cent), India Formulations (29 per cent), EMB Formulations (6 per cent), Animal Health (4 per cent), Wellness (4 per cent), API (3 per cent), Alliances (2 per cent) and Europe Formulations (2 per cent).

During the recently concluded quarter Q3FY19, the company has witnessed 10 per cent yoy increase in its revenue. However, the bottomline has declined by 6 per cent on yoy basis.

On Thursday, the stock of Cadila Healthcare opened at Rs. 329.85 per share and made an intraday high of Rs. 331.25 on the BSE. At 15:26 hours, the stock was trading nearly at Rs. 323.85 on the BSE. The company had hit its 52-week high of Rs. 432.40 on September 10, 2018 and its 52-week low of Rs. 306.35 on February 15, 2019 on the BSE.